Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × bexmarilimab × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Other hematologic neoplasm 1 Myeloid 1 Genitourinary 1 Gastrointestinal 1

Conditions

Colonic Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

pembrolizumab 62 Docetaxel 46 Nivolumab 43 Prednisone 31 enzalutamide 27 Gemcitabine 23 Paclitaxel 20 Cyclophosphamide 19 Radiotherapy 18 Cisplatin 18 Carboplatin 17 Ipilimumab 16 Abiraterone Acetate 16 Bevacizumab 13 aldesleukin 12 Magnetic Resonance Spectroscopy 12 Interleukin-2 12 fludarabine 11 atezolizumab 11 Sunitinib 11 Pluvicto 11 Filgrastim 11 Everolimus 11 gallium 68 PSMA-11 10 fludarabine phosphate 10 durvalumab 10 avelumab 10 Radiosurgery 10 cemiplimab 9 abiraterone 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05104905 2022-05-11

RENACOL

Faron Pharmaceuticals Ltd

Phase 1/2 Withdrawn

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡